Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-01-30

AUTHORS

Kazuma Hamada, Yoshihisa Shitara, Shuichi Sekine, Toshiharu Horie

ABSTRACT

PurposeThe molecular mechanisms that underlie the methotrexate (MTX)-mediated disruption of intestinal barrier function have not been fully characterized. Epithelial barrier function is determined in large part by a multiprotein complex located at the most apical part of the lateral membrane, which is referred to as a tight junction (TJ). In the present study, we examined the alteration of zonula occludens-1 (ZO-1), which is a scaffolding protein that plays a pivotal role in the formation of TJs, to identify an additional molecular mechanism for epithelial barrier dysfunction.MethodsMale Wistar rats were administered MTX (15 mg kg−1) orally once daily for 3–5 days. Intestinal mucosal permeability was determined using the in vitro everted intestinal sac technique. Mucosal inflammation was assessed by myeloperoxidase activity and production of reactive oxygen species. Altered expression, tyrosine phosphorylation, and localization of ZO-1 were evaluated by RT–PCR, Western blotting, immunoprecipitation, and immunohistochemistry.ResultsA barrier function study revealed increased intestinal permeability in rats treated with MTX for 4 days, as indicated by enhanced fluorescein isothiocyanate-dextran flux. In addition, mucosal inflammation was linked to enhanced intestinal permeability. Quantitative analysis of ZO-1 expression showed the absence of significant differences in MTX-treated rats, whereas tyrosine dephosphorylation of ZO-1 was observed. Moreover, we also detected an obvious reduction of ZO-1 immunostaining along the apical membrane of intestinal villi.ConclusionsThese results indicate that, in MTX-treated rats, ZO-1 alterations may contribute to disturbance of the TJ barrier, which leads to enhanced intestinal permeability. More... »

PAGES

1031-1038

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-010-1253-9

DOI

http://dx.doi.org/10.1007/s00280-010-1253-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034323941

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20119715


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blotting, Western", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dextrans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorescein-5-isothiocyanate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoprecipitation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Inflammation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intestinal Mucosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intestine, Small", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Luminescence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Permeability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Wistar", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reactive Oxygen Species", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reverse Transcriptase Polymerase Chain Reaction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tight Junctions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tyrosine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Zonula Occludens-1 Protein", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamada", 
        "givenName": "Kazuma", 
        "id": "sg:person.01346736417.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346736417.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shitara", 
        "givenName": "Yoshihisa", 
        "id": "sg:person.0607677165.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607677165.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sekine", 
        "givenName": "Shuichi", 
        "id": "sg:person.014523410741.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014523410741.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horie", 
        "givenName": "Toshiharu", 
        "id": "sg:person.015025434461.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015025434461.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-008-0732-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045307641", 
          "https://doi.org/10.1007/s00280-008-0732-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1119-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050833962", 
          "https://doi.org/10.1007/s00280-009-1119-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35067088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044036068", 
          "https://doi.org/10.1038/35067088"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-01-30", 
    "datePublishedReg": "2010-01-30", 
    "description": "PurposeThe molecular mechanisms that underlie the methotrexate (MTX)-mediated disruption of intestinal barrier function have not been fully characterized. Epithelial barrier function is determined in large part by a multiprotein complex located at the most apical part of the lateral membrane, which is referred to as a tight junction (TJ). In the present study, we examined the alteration of zonula occludens-1 (ZO-1), which is a scaffolding protein that plays a pivotal role in the formation of TJs, to identify an additional molecular mechanism for epithelial barrier dysfunction.MethodsMale Wistar rats were administered MTX (15\u00a0mg\u00a0kg\u22121) orally once daily for 3\u20135\u00a0days. Intestinal mucosal permeability was determined using the in vitro everted intestinal sac technique. Mucosal inflammation was assessed by myeloperoxidase activity and production of reactive oxygen species. Altered expression, tyrosine phosphorylation, and localization of ZO-1 were evaluated by RT\u2013PCR, Western blotting, immunoprecipitation, and immunohistochemistry.ResultsA barrier function study revealed increased intestinal permeability in rats treated with MTX for 4\u00a0days, as indicated by enhanced fluorescein isothiocyanate-dextran flux. In addition, mucosal inflammation was linked to enhanced intestinal permeability. Quantitative analysis of ZO-1 expression showed the absence of significant differences in MTX-treated rats, whereas tyrosine dephosphorylation of ZO-1 was observed. Moreover, we also detected an obvious reduction of ZO-1 immunostaining along the apical membrane of intestinal villi.ConclusionsThese results indicate that, in MTX-treated rats, ZO-1 alterations may contribute to disturbance of the TJ barrier, which leads to enhanced intestinal permeability.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-010-1253-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "66"
      }
    ], 
    "keywords": [
      "zonula occludens-1", 
      "intestinal permeability", 
      "mucosal inflammation", 
      "fluorescein isothiocyanate-dextran flux", 
      "barrier function", 
      "intestinal mucosal permeability", 
      "tight junctions", 
      "intestinal barrier function", 
      "MethodsMale Wistar rats", 
      "epithelial barrier dysfunction", 
      "methotrexate-treated rats", 
      "ZO-1 expression", 
      "epithelial barrier function", 
      "intestinal sac technique", 
      "myeloperoxidase activity", 
      "mucosal permeability", 
      "molecular mechanisms", 
      "barrier dysfunction", 
      "Wistar rats", 
      "additional molecular mechanisms", 
      "sac technique", 
      "barrier function studies", 
      "intestinal villi", 
      "rats", 
      "occludens-1", 
      "MTX", 
      "Western blotting", 
      "reactive oxygen species", 
      "RT-PCR", 
      "altered expression", 
      "ConclusionsThese results", 
      "TJ barrier", 
      "significant differences", 
      "inflammation", 
      "function studies", 
      "present study", 
      "alterations", 
      "pivotal role", 
      "oxygen species", 
      "tyrosine phosphorylation", 
      "apical membrane", 
      "days", 
      "dysfunction", 
      "immunohistochemistry", 
      "expression", 
      "apical part", 
      "villi", 
      "blotting", 
      "obvious reduction", 
      "lateral membranes", 
      "study", 
      "tyrosine dephosphorylation", 
      "mechanism", 
      "phosphorylation", 
      "immunoprecipitation", 
      "permeability", 
      "disruption", 
      "function", 
      "membrane", 
      "absence", 
      "differences", 
      "activity", 
      "protein", 
      "quantitative analysis", 
      "role", 
      "formation of TJs", 
      "reduction", 
      "localization", 
      "disturbances", 
      "barriers", 
      "junction", 
      "large part", 
      "part", 
      "multiprotein complexes", 
      "addition", 
      "dephosphorylation", 
      "production", 
      "analysis", 
      "results", 
      "technique", 
      "formation", 
      "complexes", 
      "species", 
      "flux"
    ], 
    "name": "Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats", 
    "pagination": "1031-1038", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034323941"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-010-1253-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20119715"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-010-1253-9", 
      "https://app.dimensions.ai/details/publication/pub.1034323941"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-010-1253-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1253-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1253-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1253-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1253-9'


 

This table displays all metadata directly associated to this object as RDF triples.

275 TRIPLES      22 PREDICATES      137 URIs      126 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-010-1253-9 schema:about N04a9c3cd9def45a894bbcfa987246e66
2 N051bb17d0beb421a98782810bcc3afa6
3 N05d6da85d4ab4cdeb8b7c54581a1a2d5
4 N13cdcebb92844213bf1c0489a228b5fd
5 N27b2112f543f468483d1f138a3cfe9b4
6 N34f809a829d34615a72bcf7ab1a4113d
7 N4307460317b248b88b977230a88f625c
8 N442fd7307db945ae9608dd2b582e13e4
9 N467857e045e646938d5a774594b224d8
10 N48793cb626024c35b9b33adc8c251335
11 N674d5fba1657416e998de55b16f24a51
12 N6a55d40b2c6b48f088ba9fc2201d95f6
13 N7d899347cfb34fd2b32f62771ec95184
14 N85ba4e109ee34e4aa26003c8c7249aee
15 N8f05c583bfbe4d1db2836e985ac9b66f
16 N95e1474f24dd4ff79fa1bc885515938a
17 N9934910ca6944f7b96b71f2ca5b7557a
18 Na22de13330b6484f88d11693cfe652e1
19 Na3df1e76f81e47298c50e494101580de
20 Ncf6d96207921441c8bdf8e3720365d76
21 Ndcb0faad7e93408ca6f1ffd6235a95c4
22 Ne1a087acbb1c4fe5b8bb7ccb007f5a23
23 Ne2b1bb5937ce4bc79afb0b610568636f
24 Nebd8d01162224125b6e28c7776ea3750
25 anzsrc-for:11
26 anzsrc-for:1115
27 schema:author Ne529fd44ca204c419d0d2ec1ce32012e
28 schema:citation sg:pub.10.1007/s00280-008-0732-8
29 sg:pub.10.1007/s00280-009-1119-1
30 sg:pub.10.1038/35067088
31 schema:datePublished 2010-01-30
32 schema:datePublishedReg 2010-01-30
33 schema:description PurposeThe molecular mechanisms that underlie the methotrexate (MTX)-mediated disruption of intestinal barrier function have not been fully characterized. Epithelial barrier function is determined in large part by a multiprotein complex located at the most apical part of the lateral membrane, which is referred to as a tight junction (TJ). In the present study, we examined the alteration of zonula occludens-1 (ZO-1), which is a scaffolding protein that plays a pivotal role in the formation of TJs, to identify an additional molecular mechanism for epithelial barrier dysfunction.MethodsMale Wistar rats were administered MTX (15 mg kg−1) orally once daily for 3–5 days. Intestinal mucosal permeability was determined using the in vitro everted intestinal sac technique. Mucosal inflammation was assessed by myeloperoxidase activity and production of reactive oxygen species. Altered expression, tyrosine phosphorylation, and localization of ZO-1 were evaluated by RT–PCR, Western blotting, immunoprecipitation, and immunohistochemistry.ResultsA barrier function study revealed increased intestinal permeability in rats treated with MTX for 4 days, as indicated by enhanced fluorescein isothiocyanate-dextran flux. In addition, mucosal inflammation was linked to enhanced intestinal permeability. Quantitative analysis of ZO-1 expression showed the absence of significant differences in MTX-treated rats, whereas tyrosine dephosphorylation of ZO-1 was observed. Moreover, we also detected an obvious reduction of ZO-1 immunostaining along the apical membrane of intestinal villi.ConclusionsThese results indicate that, in MTX-treated rats, ZO-1 alterations may contribute to disturbance of the TJ barrier, which leads to enhanced intestinal permeability.
34 schema:genre article
35 schema:inLanguage en
36 schema:isAccessibleForFree false
37 schema:isPartOf N23991cc644c446e7a183c376ffd94cf4
38 N49312f56c74942bca5e4b0f6d301a113
39 sg:journal.1088364
40 schema:keywords ConclusionsThese results
41 MTX
42 MethodsMale Wistar rats
43 RT-PCR
44 TJ barrier
45 Western blotting
46 Wistar rats
47 ZO-1 expression
48 absence
49 activity
50 addition
51 additional molecular mechanisms
52 alterations
53 altered expression
54 analysis
55 apical membrane
56 apical part
57 barrier dysfunction
58 barrier function
59 barrier function studies
60 barriers
61 blotting
62 complexes
63 days
64 dephosphorylation
65 differences
66 disruption
67 disturbances
68 dysfunction
69 epithelial barrier dysfunction
70 epithelial barrier function
71 expression
72 fluorescein isothiocyanate-dextran flux
73 flux
74 formation
75 formation of TJs
76 function
77 function studies
78 immunohistochemistry
79 immunoprecipitation
80 inflammation
81 intestinal barrier function
82 intestinal mucosal permeability
83 intestinal permeability
84 intestinal sac technique
85 intestinal villi
86 junction
87 large part
88 lateral membranes
89 localization
90 mechanism
91 membrane
92 methotrexate-treated rats
93 molecular mechanisms
94 mucosal inflammation
95 mucosal permeability
96 multiprotein complexes
97 myeloperoxidase activity
98 obvious reduction
99 occludens-1
100 oxygen species
101 part
102 permeability
103 phosphorylation
104 pivotal role
105 present study
106 production
107 protein
108 quantitative analysis
109 rats
110 reactive oxygen species
111 reduction
112 results
113 role
114 sac technique
115 significant differences
116 species
117 study
118 technique
119 tight junctions
120 tyrosine dephosphorylation
121 tyrosine phosphorylation
122 villi
123 zonula occludens-1
124 schema:name Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats
125 schema:pagination 1031-1038
126 schema:productId N006fe3b8adeb49fb84907f9f4d3d2aaa
127 N366e0dbbca6c4c5eb107cda0b24200be
128 Nccb101095b6842419e529ce6cbd0d756
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034323941
130 https://doi.org/10.1007/s00280-010-1253-9
131 schema:sdDatePublished 2022-05-20T07:26
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher Na05d27cc94424d5385085594b4dea6c3
134 schema:url https://doi.org/10.1007/s00280-010-1253-9
135 sgo:license sg:explorer/license/
136 sgo:sdDataset articles
137 rdf:type schema:ScholarlyArticle
138 N006fe3b8adeb49fb84907f9f4d3d2aaa schema:name pubmed_id
139 schema:value 20119715
140 rdf:type schema:PropertyValue
141 N04a9c3cd9def45a894bbcfa987246e66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Animals
143 rdf:type schema:DefinedTerm
144 N051bb17d0beb421a98782810bcc3afa6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Male
146 rdf:type schema:DefinedTerm
147 N05d6da85d4ab4cdeb8b7c54581a1a2d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Intestinal Mucosa
149 rdf:type schema:DefinedTerm
150 N13cdcebb92844213bf1c0489a228b5fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Inflammation
152 rdf:type schema:DefinedTerm
153 N23991cc644c446e7a183c376ffd94cf4 schema:issueNumber 6
154 rdf:type schema:PublicationIssue
155 N27b2112f543f468483d1f138a3cfe9b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Phosphoproteins
157 rdf:type schema:DefinedTerm
158 N34f809a829d34615a72bcf7ab1a4113d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Intestine, Small
160 rdf:type schema:DefinedTerm
161 N366e0dbbca6c4c5eb107cda0b24200be schema:name doi
162 schema:value 10.1007/s00280-010-1253-9
163 rdf:type schema:PropertyValue
164 N37f8ad8aad30474489bcc9717d8ef17a rdf:first sg:person.015025434461.42
165 rdf:rest rdf:nil
166 N4307460317b248b88b977230a88f625c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Membrane Proteins
168 rdf:type schema:DefinedTerm
169 N442fd7307db945ae9608dd2b582e13e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Permeability
171 rdf:type schema:DefinedTerm
172 N467857e045e646938d5a774594b224d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Antimetabolites, Antineoplastic
174 rdf:type schema:DefinedTerm
175 N48793cb626024c35b9b33adc8c251335 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Rats, Wistar
177 rdf:type schema:DefinedTerm
178 N49312f56c74942bca5e4b0f6d301a113 schema:volumeNumber 66
179 rdf:type schema:PublicationVolume
180 N674d5fba1657416e998de55b16f24a51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Reactive Oxygen Species
182 rdf:type schema:DefinedTerm
183 N6a55d40b2c6b48f088ba9fc2201d95f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Reverse Transcriptase Polymerase Chain Reaction
185 rdf:type schema:DefinedTerm
186 N7d899347cfb34fd2b32f62771ec95184 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Methotrexate
188 rdf:type schema:DefinedTerm
189 N85ba4e109ee34e4aa26003c8c7249aee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Tight Junctions
191 rdf:type schema:DefinedTerm
192 N8f05c583bfbe4d1db2836e985ac9b66f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Zonula Occludens-1 Protein
194 rdf:type schema:DefinedTerm
195 N95e1474f24dd4ff79fa1bc885515938a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Dextrans
197 rdf:type schema:DefinedTerm
198 N9934910ca6944f7b96b71f2ca5b7557a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Immunohistochemistry
200 rdf:type schema:DefinedTerm
201 Na05d27cc94424d5385085594b4dea6c3 schema:name Springer Nature - SN SciGraph project
202 rdf:type schema:Organization
203 Na22de13330b6484f88d11693cfe652e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Fluorescein-5-isothiocyanate
205 rdf:type schema:DefinedTerm
206 Na3df1e76f81e47298c50e494101580de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Immunoprecipitation
208 rdf:type schema:DefinedTerm
209 Nc2e911834355455faea9fa1114af3854 rdf:first sg:person.0607677165.24
210 rdf:rest Nc4d5917f9cf744f7a462299162be7d7c
211 Nc4d5917f9cf744f7a462299162be7d7c rdf:first sg:person.014523410741.77
212 rdf:rest N37f8ad8aad30474489bcc9717d8ef17a
213 Nccb101095b6842419e529ce6cbd0d756 schema:name dimensions_id
214 schema:value pub.1034323941
215 rdf:type schema:PropertyValue
216 Ncf6d96207921441c8bdf8e3720365d76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Rats
218 rdf:type schema:DefinedTerm
219 Ndcb0faad7e93408ca6f1ffd6235a95c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Tyrosine
221 rdf:type schema:DefinedTerm
222 Ne1a087acbb1c4fe5b8bb7ccb007f5a23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Blotting, Western
224 rdf:type schema:DefinedTerm
225 Ne2b1bb5937ce4bc79afb0b610568636f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Phosphorylation
227 rdf:type schema:DefinedTerm
228 Ne529fd44ca204c419d0d2ec1ce32012e rdf:first sg:person.01346736417.19
229 rdf:rest Nc2e911834355455faea9fa1114af3854
230 Nebd8d01162224125b6e28c7776ea3750 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Luminescence
232 rdf:type schema:DefinedTerm
233 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
234 schema:name Medical and Health Sciences
235 rdf:type schema:DefinedTerm
236 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
237 schema:name Pharmacology and Pharmaceutical Sciences
238 rdf:type schema:DefinedTerm
239 sg:journal.1088364 schema:issn 0344-5704
240 1432-0843
241 schema:name Cancer Chemotherapy and Pharmacology
242 schema:publisher Springer Nature
243 rdf:type schema:Periodical
244 sg:person.01346736417.19 schema:affiliation grid-institutes:grid.136304.3
245 schema:familyName Hamada
246 schema:givenName Kazuma
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346736417.19
248 rdf:type schema:Person
249 sg:person.014523410741.77 schema:affiliation grid-institutes:grid.136304.3
250 schema:familyName Sekine
251 schema:givenName Shuichi
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014523410741.77
253 rdf:type schema:Person
254 sg:person.015025434461.42 schema:affiliation grid-institutes:grid.136304.3
255 schema:familyName Horie
256 schema:givenName Toshiharu
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015025434461.42
258 rdf:type schema:Person
259 sg:person.0607677165.24 schema:affiliation grid-institutes:grid.136304.3
260 schema:familyName Shitara
261 schema:givenName Yoshihisa
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607677165.24
263 rdf:type schema:Person
264 sg:pub.10.1007/s00280-008-0732-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045307641
265 https://doi.org/10.1007/s00280-008-0732-8
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s00280-009-1119-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050833962
268 https://doi.org/10.1007/s00280-009-1119-1
269 rdf:type schema:CreativeWork
270 sg:pub.10.1038/35067088 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044036068
271 https://doi.org/10.1038/35067088
272 rdf:type schema:CreativeWork
273 grid-institutes:grid.136304.3 schema:alternateName Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan
274 schema:name Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, 260-8675, Chuo-ku, Chiba, Japan
275 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...